Look out, GSK. Pfizer has its adult RSV vaccine approval and is raring to launch

fiercepharma.com About a month after GSK won the world's first approval for a respiratory syncytial virus (RSV) vaccine, rival Pfizer has followed suit. | After winning FDA approvals one…

Is Pfizer Stock A Buy As It Leaps Into The Red-Hot Weight-Loss Race?

investors.com stock bounded higher in mid-May on enthusiasm for its potential rival to Novo Nordisk (NVO) and Eli Lilly (LLY) in diabetes treatment and weight loss. Pfizer tested its…

The 10 High Quality, Undervalued Companies

morningstar.com Investors have endured a lot of market uncertainty during the past year—and many market watchers expect volatility to persist for the foreseeable future. During uncertain…

FDA approves RSV vaccine for older adults

axios.com The Food and Drug Administration on Wednesday approved Pfizer's vaccine against respiratory syncytial virus for people aged 60 and older, making it the second RSV shot…

FDA approves Pfizer RSV vaccine for older adults

thehill.com The Food and Drug Administration (FDA) on Wednesday approved Pfizer’s vaccine to prevent the respiratory disease RSV in older adults, the company announced. After decades…

FDA Approves Pfizer’s RSV Vaccine For Older Adults

forbes.com The Food and Drug Administration on Wednesday approved Pfizer’s vaccine to protect older adults from RSV, weeks after the agency greenlit the very first shot against the…

FDA Approves Pfizer’s RSV Vaccine for Adults 60 and Older

nytimes.com Why It Matters: Older adults are at a higher risk. Each year, about 60,000 adults 65 and older are hospitalized with R.S.V. and about 6,000 to 10,000 die from the virus, the…

FDA approves Pfizer’s RSV shot for older adults, teeing up a competitive $17B vaccine market

endpts.com The FDA approved Pfizer’s RSV vaccine called Abrysvo for older adults on Wednesday, placing another Big Pharma onto the commercial stage ahead of the next RSV season.…

GSK’s CEO says you need thick skin if you’re going to step into the C-suite

fortune.com On this week’s episode of Fortune‘s Leadership Next podcast, co-hosts Alan Murray and Michal Lev-Ram talk with GSK CEO Emma Walmsley about the future of A.I. in the…

Is Moderna Stock A Buy After Unexpectedly Turning A First-Quarter Profit?

investors.com reported an unexpected profit in the first quarter, but Moderna stock is now trending sideways amid plummeting Covid vaccine sales. X Moderna is well on the other side of…

Science finally figured out how to make effective RSV vaccines. Will seniors care?

statnews.com The world has waited decades for vaccines to protect older adults against RSV. One, made by GSK, was approved by the Food and Drug Administration earlier this month. A…

Britain is on the brink of a retirement crisis

yahoo.com Across government and the city, policymakers and politicians are singing from the same hymn sheet: the City of London needs to start taking more risks. Britain is facing a…

Gucci-Owner Kering, Drugmaker GSK and Others Are Developing Global Targets on Nature Loss

wsj.com Luxury group Kering and biopharma company GSK are among more than a dozen companies preparing targets to develop a gold standard for how businesses can protect nature. In…

First RSV Vaccine Caps 60-Year Search to Stem Lung Illness

youtube.com For 60 years, doctors and scientists searched for a vaccine against a common virus that, while sometimes deadly, is little known to the public. The hunt is over. The US Food…